The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Merck shared updates on the company’s oncology pipeline and focused R&D approach
With this, for all our USFDA facilities, EIRs are in place
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The facility will manufacture tablets, capsules, and injections for the oncology segment
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated
